Sep
11
14th International Symposium/8th European Conference on Marine Natural Products to favour creation of European consortia and mobility of researchers
This leading scientific event, to be held on La Toja Island (Pontevedra, Spain), is accompanied by a major worldwide communication campaign
The identification and subsequent reproduction of marine specimens in laboratories is one of the industry’s main challenges
Alberto Núñez Feijóo, President of Galicia’s regional government, will participate in the opening ceremony in support of RD and innovation
Madrid, 10 September 2013:MaNaPro, the 14th International Symposium on Marine Natural Products (www.manapro2013.com), was presented today in Madrid. The event will be held from 15 to 20 September 2013 on La Toja Island (Pontevedra, Spain). MaNaPro is the world’s leading scientific event on marine- based products, and this year it will held in conjunction with the European Conference on Marine Natural Products for the first time. “This is also the first time in 37 years that MaNaPro has been organized by a pharmaceutical company, in this case PharmaMar (Grupo Zeltia), working very closely with the Galician Innovation Agency, which is part of the Galicia Regional Ministry of Economy and Industry. “Because of the scientific importance and relevance of this event, it is accompanied by one of the largest-evermedia campaigns on RD and innovation in marine biotechnology worldwide”, says José María Fernández Sousa-Faro, Chairman of PharmaMar.
The event will be attended by scientists from 38 countries on 5 continents including many young researchers working in marine biotechnology. Carmen Cuevas, Director of RD at PharmaMar and Chair of the Symposium: “We believe this triennial event will encourage the creation of European consortia as well as technology use and transfer and researcher mobility”.
In this context, “The identification of marine specimens and their subsequent reproduction in the lab is one of this area’s greatest challenges”, she adds. “We believe this will give rise to a new wave of compounds which could be crucial in addressing immune system disorders and cancer”. The Symposium will showcase the latest developments and discoveries related to marine ecosystems, biodiversity, biosynthesis, and bioprospecting, along with information on novel technologies to isolate and determine the chemical structure of new molecules.
Under its commitment to RD and innovation, the Galician government has been fully supportive ofPharmaMar’s proposal to hold the event in Galicia, and Galician President, Alberto Núñez Feijóo, will participate in the MaNaPro opening ceremony. Other notable participants will include Carmen Vela, Spain’s Secretary of State for RD and Innovation; Regina Revilla, Chairman of the Spanish Bioindustry Association (ASEBIO); Antonio Figueras, Vice-Chairman of Spain’s Higher Council for Scientific Research (CSIC); and Miguel Ángel Pérez García, Mayor of O Grove. Manuel Varela, Director of the Galician Innovation Agency: “Our objectives include supporting the development and dissemination of scientific knowledge and technology in Galicia by promoting interest in research, development and innovation within society. This is in line with one of the strategic principles underlying the 2011-2015 Galician Plan for Research, Innovation and Growth, I2=C”.
About PharmaMar
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is the first marine-based antitumour drug. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major RD programme.
About Zeltia
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine- based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain’s leading company in molecular
diagnostics based on DNA analysis; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).
Important note
PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Zeltia, S.A. (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain’s Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.
For more information +34 91 444 4500
This note is also available on the PharmaMar web site: www.pharmamar.com and at Zeltia’s website:
distributed by
Open all references in tabs: [1 – 3]
Comments
Leave a Reply
You must be logged in to post a comment.